A Study of the Effect of Plasmaexchange in Patients With Acute Liver Failure

The aim of this study is to examine if high-volume plasma exchange has a positive effect on mortality in patients with acute liver failure.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Liver Failure Digestive System Diseases Hepatic Insufficiency Liver Diseases Liver Failure Liver Failure, Acute

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Hepatology, Rigshospitalet, Copenhagen, DK, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with acute liver failure in encephalopathy grade 2-4

Exclusion criteria

alcoholic hepatitis
primary non function liver graft or graft dysfunction
known chronic liver disease
known malignancies
clinical suspicion of brain death

Treatment and study plan

High volume plasma exchange

Procedure

3 high volume plasma exchanges over 3 days

Other names: HVP

Standard medical treatment

Procedure

Standard medical treatment

Other names: SMT

Primary outcomes

mortality

Time frame: at day 3, day 7

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Registry information

Official study title

European Multicenter Plasma Exchange Trial (Empet): A Controlled, Open, Randomised, Multicenter Study In Patients With Acute Liver Failure

Important dates

Study start: 1998
Primary completion: 2009
Study completion: 2009
First posted: Jul 31, 2009
Registry last updated: Nov 5, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed